Subscribe Now
 Already a subscriber? Log-in!
By subscribing to Laboratory Industry Report, each month you'll get an insider's view of the lab industry's most important business and financial trends, plus predictions for the coming year.
In each issue, you find:
- Comparative data on lab pricing
- Information and explanations describing how to deal with healthcare integration, capitation, technology advances, etc.
- Clear perspectives of how your firm is performing vs. the market at large How publicly-traded lab companies are performing and what their top executives earn
- Updates on late-breaking mergers & acquisitions.
Are you up on what's working—and what's not—for laboratories located in a variety of practice settings-hospital, commercial, group practice sites and network systems?
More importantly, do you know where to turn for business intelligence & insight when you need to know what's happening to key companies, how Wall Street views the industry, or the latest scoop on mergers, buyouts, consolidations and alliances?
Laboratory Industry Report is a must for everyone having a vital stake in today's competitive lab marketplace-owner, director, pathologist, CEO, COO, CFO, general manager, administrator, manager, marketeer, or vendor.
With Laboratory Industry Report, you'll get all the business news & insights which are accurate, objective, reliable, and authoritative. Gain a competitive edge for your company or institution today by subscribing today!
|
|
|
 |
 | LIR June 2008 (full PDF issue) |
| TOP OF THE NEWS
Prices plunging on DTC Tests
Global mol dx market to climb to $8B by 2010
LAB METRIC ANALYSIS
Quest, LabCorp rev./req. strong in Q1
LAB PARTNERSHIPS
LabCorp and Siemens team up
JVHL partners with Clarient
INSIDE THE LAB INDUSTRY
Deep financial analysis vital to making mol dx lab a success
BENCHMARKS
Benchmarking Q1 08 data for labs
CONTRACT NEWS
Orchid Cellmark lands U.K. forsenic testing contract
FINANCIAL
Lab index up 8%
INDUSTRY BUZZ
Genzyme Genetics to expand Santa Fe staff
Full Article |
| G-2 Predicts Global Mol Dx Industry to Reach $5.5 Billion in 2008, $8 Billion by 2010 |
| While most segments of the lab market continue to grow at 5 percent per year, the molecular diagnostics market continues to grow at approximately 20 percent to an approximate total of $5.5 billion in 2008, according to Washington G-2 Reports’s estimates. This growth is expected to accelerate, with this area of lab testing estimated to value $8 billion by 2010, noted G-2’s Stephanie Murg, editor of the Diagnostic Testing & Technology Report, at a conference, Business & Financial Strategies for Molecular Diagnostics, held April 30 to May 2 in Cambridge, Massachusetts.
Full Article |
| Prices Dropping on Some DTC Genetic Tests as SACGHS Urges Tighter Regs |
| At least 30 direct-to-consumer (DTC) genetic testing companies have emerged over the past two years, many selling testing services for far below the thousands of dollars charged by genome sequencing services like 23andMe and Knome, explained Trish Brown, vice president of clinical affairs for DNA Direct (San Francisco), at the recent 2008 Executive War College, held May 13 and 14 in Miami, Florida. While these new companies are spurring more pricing competition among DTC genetic testing providers, it’s also attracting the attention of regulators, including the Secretary’s Advisory Committee on Genetics Health and Society (SACGHS), which recently called for increased regulatory oversight of all genetic tests, as well as laboratory tests.
Full Article |
| Quest, LabCorp Revenue/Requisition Metrics Strengthen in Q1 |
| Despite confronting sluggish organic growth, the nation’s two largest lab testing providers posted strong revenue per requisition numbers in the first quarter of this year, indicating that the private payor environment is improving, according to analysts at Chicago-based William Blair & Company (WB&C).
Full Article |
| LabCorp’s Partners With Siemens, Acquires Louisiana Lab |
| LabCorp (Burlington, NC) and leading in vitro diagnostic manufacturer Siemens Healthcare (Deerfield, Ill.) have entered into a nonexclusive agreement to pursue co-development of diagnostics tests relating to companion diagnostics, metabolic syndrome, oncology, and diabetes, both companies recently announced.
Full Article |
| Cost and Profit Analysis Is Key to Capturing Revenue Potential of Mol Dx Lab |
| Higher reimbursement rates and a demand for multiplex testing and workflow improvements are driving the global molecular diagnostic testing market to an estimated $5.5 billion dollars this year and a projected $10 billion in 2010. Analysis of revenue per requisition at commercial labs in 2007 reveals the higher reimbursement levels of these tests are leading many of these labs to put more focus on this business area in the future (see graph). For example, while molecular diagnostic testing was only comprising 3 percent of LabCorp’s (Burlington, N.C.) volumes in 2002, it was contributing 17 percent to its revenues. Currently, the company is said to derive 22 percent of its revenue from genomic and esoteric testing and is hoping this will increase to 40 percent in the next few years.
Full Article |
| Q1 08 Lab Benchmark Data Reveal Psychemedics Still a Leader, Enzo Posts Gains |
| After analyzing financial data of nine publicly traded labs from the first quarter of 2008, Washington G-2 Reports finds that Psychemedics (Acton, Mass.), had the highest revenue per full-time employee (FTE) with $60,638, which is essentially the same as the Q1 2007 value, as the company’s revenue over that time period has remained flat. With 97 FTEs, Psychemedics performs drug-of-abuse testing through corporate and school programs. Psychemedics also led in both benchmarks in G-2’s analysis of 2007 data (LIR, May 2008).
Full Article |
| JVHL Teams With Clarient to Expand Cancer AP Menu |
| The 120 hospital-affiliated labs comprising the Michigan-based Joint Venture Hospital Laboratories (JVHL; Allen Park) are expanding their anatomic pathology (AP) and molecular diagnostic cancer testing offerings through a recently formed partnership with Clarient, a molecular diagnostic and AP specialty lab based in Aliso Viejo, California. Under the current one-year agreement, Clarient will do the technical work at its facility and send the results to JVHL pathologists through its Web-based application, PathSite. The pathologists will then perform the professional interpretation and manage those results with local clinicians.
Full Article |
| Orchid Cellmark Wins $30 Million Forensic Testing Contract in U.K. |
| DNA testing service provider Orchid Cellmark (Princeton, N.J.) has won a regional tender in the United Kingdom to provide forensic testing services to multiple police forces in the western areas of the country and Wales. The three-year contract has a potential annual revenue value of $10 million, with two optional extension years, making the entire contract potentially worth between $30 million and $50 million.
Full Article |
| Lab Stocks Continue to Post Gains in May, up 8% Over 5 Weeks |
| The G-2 Laboratory Index continues to show strength, with the 14 publicly traded laboratory stocks up 8 percent over the past five weeks for the week ended May 16, 2008. For the entire year, however, the Lab Index is down 6 percent, while the Nasdaq and S&P 500 continue to feel the impact of the sluggish economy. The Nasdaq is down 5.44 percent and the S&P 500 is down 3.59 percent so far in 2008.
Full Article |
| Economic Development Incentives Fuel Genzyme Genetics’s Staff Expansion in Santa Fe |
| Tax breaks and other economic incentives from the state of New Mexico are behind Genzyme Genetics’s (Cambridge, Mass.) plans to expand its Santa Fe operations by 45 full-time employees (FTEs) over the next three years. There are over 1,700 FTEs in the entire Genetics’s division, with 300 currently located at the Santa Fe location.
Full Article |
|
|
Please choose an archived issue to view newsletter table of contents above
|
|
